Lead Product(s): Idursulfase beta
Therapeutic Area: Genetic Disease Product Name: Hunterase
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: 3W Fund Management
Deal Size: $43.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing December 01, 2020
The proceeds will be used to expand the CANbridge rare disease pipeline through internal development and external partnerships, accelerate the clinical development of pre-clinical stage assets, prepare the commercial launch of Hunterase® and supplement working capital.